ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0407

Achievement of Early and Sustained Complete Response of Oral Ulcers with Apremilast Compared with Placebo in Patients with Active Behçet’s Syndrome

Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu1, Sue Cheng5, Sven Richter5, Michele Brunori6, Maria Paris5, Mindy Chen5 and Yusuf Yazici7, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Amgen Inc., Thousand Oaks, 6Amgen Europe GmbH, Rotkreuz, Switzerland, 7New York University School of Medicine, New York

Meeting: ACR Convergence 2020

Keywords: Behçet's Syndrome, Ulcers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Painful and recurring oral ulcers (OU) are a common manifestation of Behçet’s syndrome that can interfere with eating and have a negative impact on quality of life (Ozguler Y, et al. Clin Exp Rheumatol. 2019;37[6 Suppl 121]:28‐34). Apremilast (APR), an oral phosphodiesterase 4 inhibitor, has demonstrated efficacy in the treatment of OU in the phase 3 RELIEF study (Hatemi G, et al. N Engl J Med. 2019;381:1918-1928). In RELIEF, 53% of patients treated with APR 30 mg BID and 22% who received placebo (PBO) achieved OU complete response at Week 12 (Hatemi G, et al. N Engl J Med. 2019;381:1918-1928). Here, we describe the achievement of OU complete response over different time points during the PBO-controlled period in RELIEF.

Methods: This multicenter, randomized, double-blind, PBO-controlled study (BCT-002; NCT02307513) enrolled adult patients (≥18 years of age) with active Behçet’s syndrome and ≥3 OU at randomization or ≥2 OU at screening and randomization, without active major organ involvement. Patients were randomized (1:1) to receive APR or PBO during the 12-week PBO-controlled period. The current post hoc analysis assessed the proportion of individual patients who achieved OU complete response (ie, were OU-free) at any point during the PBO-controlled period and the proportion of patients who achieved complete response for OU as early as Weeks 1 or 2. The number of patients achieving OU complete response by Week 6 who remained OU-free for ≥6 additional weeks was also evaluated. Data are summarized descriptively.

Results: A total of 207 patients were randomized and received ≥1 dose of study medication, including 104 who received APR and 103 who received PBO. At baseline, the mean (SD) number of OU was 4.2 (3.7) in the APR group and 3.9 (2.7) in the PBO group. Mean (SD) duration of Behçet’s syndrome at baseline was 6.7 (7.4) years in the APR group and 6.9 (8.0) years in the PBO group. The proportion of individual patients who achieved OU complete response at any time point during the 12-week PBO-controlled period was higher with APR than with PBO (Figure 1). Greater proportions of patients achieved early OU complete response during Weeks 1 or 2 with APR compared with PBO (Figure 2). In total, 44/104 patients receiving APR and 24/103 patients receiving PBO had OU complete response by Week 6; of these, 33 patients in the APR group and 12 in the PBO group maintained OU-free response for ≥6 additional weeks.

Conclusion: In the RELIEF study, a higher proportion of patients with active Behçet’s syndrome achieved OU complete response with APR treatment compared with PBO  during the PBO-controlled period. Similarly, a greater proportion of patients achieved early OU complete response and maintained OU-free response with APR compared with PBO.


Disclosure: G. Hatemi, BMS, 1, Celgene Corporation, 1, Silk Road Therapeutics, 1, AbbVie, 1, Mustafa Nevzat, 1, Novartis, 1, UCB, 1, Bayer, 1, Eli Lilly, 1; A. Mahr, Roche, 1, Chugai, 1; M. Takeno, Celgene Corporation, 1, Esai, 1, Tanabe-Mitsubishi, 1; D. Kim, None; M. Melikoğlu, None; S. Cheng, Amgen Inc., 1; S. Richter, Amgen Inc., 1; M. Brunori, Amgen Europe GmbH, 1; M. Paris, Amgen Inc., 1; M. Chen, Amgen Inc., 1; Y. Yazici, BMS, 1, Celgene Corporation, 1, Genentech, 1, Sanofi, 1.

To cite this abstract in AMA style:

Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, Richter S, Brunori M, Paris M, Chen M, Yazici Y. Achievement of Early and Sustained Complete Response of Oral Ulcers with Apremilast Compared with Placebo in Patients with Active Behçet’s Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/achievement-of-early-and-sustained-complete-response-of-oral-ulcers-with-apremilast-compared-with-placebo-in-patients-with-active-behcets-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/achievement-of-early-and-sustained-complete-response-of-oral-ulcers-with-apremilast-compared-with-placebo-in-patients-with-active-behcets-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology